MinorDirect oral anticoagulants (factor Xa inhibitors)×Drugs for peptic ulcer and GORD. Proton pump inhibitors
Updated · Methodology
Mechanism
Apixaban has multiple elimination routes. It is metabolised mainly by CYP3A4/5, with minor contributions from CYP1A2, CYP2C8, CYP2C9, CYP2C19 and CYP2J2. Renal excretion accounts for about 27% of total clearance, and much of the dose is eliminated in faeces (apixaban SmPC, European Medicines Agency, EMA, section 5.2). Reducing gastric acidity does not affect apixaban: famotidine 40 mg changed neither apixaban AUC nor Cmax. Apixaban inhibits CYP2C19 only at concentrations far above those seen in patients (apixaban SmPC, EMA, section 4.5). Esomeprazole is completely metabolised by cytochrome P450, mainly by CYP2C19 and the remainder by CYP3A4, and itself inhibits CYP2C19 (esomeprazole SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, sections 4.5 and 5.2). Its SmPC lists the CYP2C19-metabolised drugs with which it may interact, such as diazepam, citalopram, imipramine, clomipramine and phenytoin. Apixaban is not among them (AEMPS, section 4.5).
Symptoms
The documents describe no symptoms caused by this combination. Apixaban increases the risk of bleeding. The most common adverse reactions are haemorrhage, contusion, epistaxis and haematoma (apixaban SmPC, European Medicines Agency, EMA, sections 4.4 and 4.8). With long-term treatment, esomeprazole, like other acid-suppressing drugs, can reduce the absorption of vitamin B12 (esomeprazole SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.4).
Management
According to the documents, the combination is acceptable and no dose change of apixaban or esomeprazole is needed. Neither document names the pair, reduced gastric acidity does not affect apixaban, and apixaban is not among the drugs whose metabolism esomeprazole may slow (apixaban SmPC, European Medicines Agency, EMA, section 4.5; Nexium SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.5). Apixaban is used with caution in conditions with an increased risk of bleeding and is stopped if severe haemorrhage occurs (apixaban SmPC, EMA, section 4.4).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Esomeprazol (nº registro 63436), sección 4.5 (2025)– AEMPS, CIMA, nº registro 63436, sección 4.5
- AEMPS: Ficha técnica de Eliquis 5 mg comprimidos recubiertos con película (apixabán) (2026)– AEMPS, CIMA (texto EMA), nº registro 111691009, secciones 4.4 y 4.5